The Synergistic Effect of SAHA and Parthenolide in MDA-MB231 Breast Cancer Cells

Journal of Cellular Physiology

Volumn 230, Issue 6, 2015, Pages 1276-1289

  Carlisi, Daniela ^a   Lauricella, Marianna ^a   D'Anneo, Antonella ^a   Buttitta, Giuseppina ^a   Emanuele, Sonia ^a   di Fiore, Riccardo ^a   Martinez, Roberta ^a   Rolfo, Christian ^b   Vento, Renza ^a,c   Tesoriere, Giovanni ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYTOCHROME C; DNA METHYLTRANSFERASE 1; GLUTATHIONE; HISTONE H3; HISTONE H4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PARTHENOLIDE; PROTEIN KINASE B; PROTEIN S6; REACTIVE OXYGEN METABOLITE; S6 KINASE; TRANSCRIPTION FACTOR NRF2; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SESQUITERPENE;

ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER CELL LINE; CELL HYPOXIA; CELL MEMBRANE DEPOLARIZATION; CELL PROTECTION; CELL SURVIVAL; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; CYTOTOXICITY; DNA BINDING; DNA METHYLATION; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; HISTONE ACETYLATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSLATION INITIATION; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NF-KAPPA B; SESQUITERPENES;

EID: 84923272543     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24863     Document Type: Article

References (50)

1. Baldwin AS. 2001. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 107:241-246.
2. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K. 2005. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 11:6382-6389.
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. 2007. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 109:1721-1728.
4. Bayraktar S, Glück S. 2013. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 138:21-35.
5. Biederbick A, Kern HF, Elsässer HP. 1995. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol 66:3-14.
6. Carlisi D, D'Anneo A, Angileri L, Lauricella M, Emanuele S, Santulli A, Vento R, Tesoriere G. 2011. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 226:1632-1641.
7. Carlisi D, D'Anneo A, Martinez R, Emanuele S, Buttitta G, Di Fiore R, Vento R, Tesoriere G, Lauricella M. 2014. The oxygen radicals involved in the toxicity induced by parthenolide in MDA-MB-231 cells. Oncol Rep 32:167-172.
8. Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC. 2013. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS ONE 8: e79781.
9. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
10. D'Anneo A, Carlisi D, Lauricella M, Emanuele S, Di Fiore R, Vento R, Tesoriere G. 2013a. Parthenolide induces caspase-independent and AIF-mediated cell death in human osteosarcoma and melanoma cells. J Cell Physiol 228:952-967.
11. D'Anneo A, Carlisi D, Lauricella M, Puleio R, Martinez R, Di Bella S, Di Marco P, Emanuele S, Di Fiore R, Guercio A, Vento R, Tesoriere G. 2013b. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis 4: e891.
12. Dey N, Smith BR, Leyland-Jones B. 2012. Targeting basal-like breast cancers. Curr Drug Targets 13:1510-1524.
13. Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R, Tesoriere G. 2007. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12:1327-1338.
14. Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. 2012. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A 109:6561-6565.
15. García-Piñeres AJ, Lindenmeyer MT, Merfort I. 2004. Role of cysteine residues of p65/NF-kB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sciences 75:841-856.
16. Ghantous A, Sinjab A, Herceg Z, Darwiche N. 2013. Parthenolide: From plant shoots to cancer roots. Drug Discov Today 18:894-905.
17. Gordy C, He YW. 2012. The crosstalk between autophagy and apoptosis: Where does this lead. Protein Cell 3:17-27.
18. Guerrant W, Patil V, Canzoneri JC, Oyelere AK. 2012. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J Med Chem 55:1465-1477.
19. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC. 2007. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110:4427-4435.
20. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. 2010. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 116:5983-5990.
21. Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K, Denk H. 2008. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 216:495-504.
22. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. 2013. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol 1:45-49.
23. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. 2001. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chem Biol 8:759-766.
24. Lauricella M, Ciraolo A, Carlisi D, Vento R, Tesoriere G. 2012. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie 94:287-299.
25. Li J, Liu R, Lei Y, Wang K, Lau QC, Xie N, Zhou S, Nie C, Chen L, Wei Y, Huang C. 2010. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy 6:711-724.
26. Liang B, Kong D, Liu Y, Liang N, He M, Ma S, Liu X. 2012. Autophagy inhibition plays the synergetic killing roles with radiation in the multi-drug resistant SKVCR ovarian cancer cells. Radiat Oncol 7: 213.
27. Liu JW, Cai MX, Xin Y, Wu QS, Ma J, Yang P, Xie HY, Huang DS. 2010a. Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res 29: 108.
28. Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P, Aimiuwu J, Pang J, Bhasin D, Neviani P, Fuchs JR, Plass C, Li PK, Li C, Huang TH, Wu LC, Rush L, Wang H, Perrotti D, Marcucci G, Chan KK. 2009. Modulation of DNA Methylation by a Sesquiterpene Lactone Parthenolide. J Pharmacol Exp Ther 329:505-514.
29. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. 2010b. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 6:1057-1065.
30. Lo Piccolo J, Blumenthal GM, Bernstein WB, Dennis PA. 2008. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist Updat 11:32-50.
31. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10:457-468.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
33. Marks PA, Xu WS. 2009. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107:600-608.
34. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. 2004. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 101:540-545.
35. Nguyen T, Sherratt PJ, Pickett CB. 2003. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43:233-260.
36. Pi J, Bai Y, Reece JM, Williams J, Liu D, Freeman ML, Fahl WE, Shugar D, Liu J, Qu W, Collins S, Waalkes MP. 2007. Molecular mechanism of human Nrf2 activation and degradation: Role of sequential phosphorylation by protein kinase CK2. Free Radic Biol Med 42:1797-1806.
37. Riedl SJ, Shi Y. 2004. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5:897-907.
38. Robertson KD. 2005. DNA methylation and human disease. Nat Rev Genet 6:597-610.
39. Rubinstein AD, Kimchi A. 2012. Life in the balance - a mechanistic view of the crosstalk between autophagy and apoptosis. J Cell Sci 15:5259-5268.
40. Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. 2013. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Exp Hematol 41:799-807.
41. Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ. 2011. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kB and generating reactive oxygen species. Int J Cancer 128:2481-2494.
42. Shanmugam R, Kusumanchi P, Cheng L, Crooks P, Neelakantan S, Matthews W, Nakshatri H, Sweeney CJ. 2010. A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. Prostate 70:1074-1086.
43. Slingerland M, Guchelaar HJ, Gelderblom H. 2014. Histone deacetylase inhibitors: An overview of the clinical studies in solid tumors. Anticancer Drugs 25:140-149.
44. Sun Y, St Clair DK, Xu Y, Crooks PA, St Clair WH. 2010. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res 70:2880-2890.
45. Suvannasankha A, Crean CD, Shanmugam R, Farag SS, Abonour R, Boswell HS, Nakshatri H. 2008. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res 14:1814-1822.
46. Wirawan E, Vande Walle, Kersse L, Cornelis K, Claerhout S, Vanoverberghe S, Roelandt I, De Rycke R, Verspurten R, Declercq J, Agostinis W, Vanden P, Berghe T, Lippens S, Vandenabeele P. 2010. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 1: e18.
47. Wyrebska A, Szymański J, Gach K, Piekielna J, Koszuk J, Janecki T, Janecka A. 2013. Apoptosis-mediated cytotoxic effects of parthenolide and the new synthetic analog MZ-6 on two breast cancer cell lines. Mol Biol Rep 40:1655-1663.
48. Yoo CB, Jones PA. 2006. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37-50.
49. Zhang S, Ong CN, Shen HM. 2004. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 208:143-153.
50. Zunino SJ, Ducore JM, Storms DH. 2007. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukaemia cells. Cancer Lett 254:119-127.